(a) The program:
(1) must collaborate with physicians and health care providers to notify a prospective subject about the program when:
(A) the prospective subject provides informed consent for a cancer clinical trial; or
(B) funding is available to provide the program for the cancer clinical trial in which the prospective subject participates;
(2) must reimburse subjects based on financial need, which may include reimbursement to subjects whose income is at or below 700 percent of the federal poverty level;
(3) must provide reimbursement for ancillary costs, including costs described by Section 51.0002, to eliminate the financial barriers to enrollment in a clinical trial;
(4) may provide reimbursement for reasonable ancillary costs, including costs described by Section 51.0002, to one family member, friend, or other person who attends a cancer clinical trial to support a subject; and
(5) must comply with applicable federal and state laws.
(b) The independent, third-party organization administering the program shall provide written notice to prospective subjects of the requirements described by Subsection (a).